A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
Abstract Background The aim of this study is to demonstrate that capecitabine metronomic chemotherapy is non-inferior to capecitabine conventional chemotherapy as maintenance treatment, in patients who have responded to 16–18 weeks first-line chemotherapy in metastatic colorectal cancer (mCRC). Meth...
Main Authors: | Min Shi, Tao Ma, Wenqi Xi, Jinling Jiang, Junwei Wu, Chenfei Zhou, Chen Yang, Zhenggang Zhu, Jun Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-4194-6 |
Similar Items
-
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
by: Xiuwen Guan, et al.
Published: (2020-07-01) -
Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis
by: Bradley Ashley Gue Ong, et al.
Published: (2022-04-01) -
Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
by: Longjiang She, et al.
Published: (2022-09-01) -
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
by: Yue Chai, et al.
Published: (2023-08-01) -
Metronomic Chemotherapy in Prostate Cancer
by: Piotr J. Wysocki, et al.
Published: (2022-05-01)